We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GENERIC DRUGMAKER PLEADS GUILTY TO FELONY CHARGES

GENERIC DRUGMAKER PLEADS GUILTY TO FELONY CHARGES

June 23, 2006

Vintage Pharmaceuticals, a generic drug manufacturer, has pleaded guilty to felony charges of distributing adulterated drugs through interstate commerce.

According to the U.S. Attorney's Office in the Western District of North Carolina, Vintage admitted that from January to October 2000 it introduced roughly 50 million tablets of Levothyroxine Sodium, USP -- a drug aimed at controlling hypothyroidism -- into commerce, knowing that its methods to assign expiration dates on the drugs did not conform with good manufacturing practices set by the FDA.

Since the tablets did not meet purported quality and purity characteristics, the U.S. Attorney's Office said, they risked falling below the FDA-required potency limits before the expiration date placed on the label, and consumers who relied on the drug could not be sure it was safe and effective.

William Propst Sr., president and CEO of Vintage, pleaded guilty to 19 misdemeanor counts of distributing adulterated drugs. His son, William Propst Jr., assistant to the president during this time period, pleaded guilty to one misdemeanor count of the same nature.

In a separate pleading, Frances Hutchins, ex-manager of Vintage's Charlotte operations, pleaded guilty to one misdemeanor count of distributing adulterated drugs into interstate commerce, adding that she failed in her duty to refuse an order from Vintage's president to release the adulterated lots of Levothyroxine Sodium, USP.

Vintage will pay $4.8 million in fines and forfeit $1.2 million in proceeds from criminal activity.

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing